Loading
GB
Generation Bio Co. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Jan 2025.
Generation Bio Co.: what insiders have been doing
Generation Bio Co., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 12 insiders have disclosed 19 filings since 18 October 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 19 filings here. Our records for Generation Bio Co. go back to 2021, with 10 purchases and 17 sales on the open market in total.
Over the last twelve months, not one insider purchase of Generation Bio Co. stock was filed. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
153
Thresholds
n/a
Buy Volume
€897,196
10 ops. · all time
Sell Volume
€4M
17 ops. · all time
Who traded when
BuySaleAnthony G. Quinn1 buy
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$17.1M
Net income-US$113.4M-661.9% margin
Last declaration on 9 February 2026
Declarations153 total
711,193 sharesCommon StockSEC:0001231919-26-000124:0
4,752 sharesCommon StockSEC:0001104659-26-012197:0
53,475 sharesCommon StockSEC:0001104659-26-012196:0
711,193 sharesCommon StockSEC:0001104659-26-012195:0
29,928 sharesCommon StockSEC:0001104659-26-012194:0
21,357 sharesCommon StockSEC:0001104659-26-012193:0
138,492 sharesCommon StockSEC:0001104659-26-012192:0
3,759 sharesCommon StockSEC:0001104659-26-012190:0
950 sharesCommon StockSEC:0001104659-26-012189:0
2,072 sharesCommon StockSEC:0001104659-26-012188:0
13,142 sharesCommon StockSEC:0001104659-26-012184:0
1,263 sharesCommon StockSEC:0001104659-26-012182:0
1,582 sharesCommon StockSEC:0001732701-26-000004:0
235 sharesCommon StockSEC:0002051408-26-000005:0
1,673 sharesCommon StockSEC:0001828153-26-000004:0
59 sharesCommon StockSEC:0002051408-26-000002:0
335 sharesCommon StockSEC:0001828153-26-000002:0
395 sharesCommon StockSEC:0001732701-26-000002:0
659 sharesCommon StockSEC:0001732701-25-000007:0
58 sharesCommon StockSEC:0002051408-25-000004:0
114 sharesCommon StockSEC:0001946316-25-000004:0
159 sharesCommon StockSEC:0001907682-25-000004:0
334 sharesCommon StockSEC:0001828153-25-000004:0
527 sharesCommon StockSEC:0001732701-25-000004:0
3,347 sharesCommon StockSEC:0001415889-25-019924:0
25 of 153 declarations
About Generation Bio Co.
Generation Bio Co. (ticker: GBIO) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. Headquartered in Cambridge, Massachusetts, it operates in one of the most competitive areas of life sciences: genetic medicines and next-generation gene therapy platforms. The company was founded in the late 2010s and came public in 2019, originally framing itself as a developer of durable, redosable genetic medicines for both rare and prevalent diseases.
Generation Bio’s current strategic focus has shifted toward T cell-driven autoimmune diseases. Its core business is centered on a proprietary cell-targeted lipid nanoparticle platform, or ctLNP, designed to deliver genetic payloads to specific cell types in vivo. The platform is intended to address one of the field’s major scientific bottlenecks: achieving selective, efficient and well-tolerated delivery of genetic cargo without broad off-target uptake. In parallel, the company has also discussed its immune-quiet DNA, or iqDNA, technology, which reflects its broader expertise in genetic medicine engineering.
Read moreShow less
From a market-position standpoint, GBIO is a small-cap, development-stage biotech rather than a commercial-stage pharmaceutical company. That means its investment case is driven primarily by technology validation, preclinical and clinical milestones, and strategic optionality, not by product sales. Its competitive set includes other gene therapy, RNA therapeutics and delivery-platform developers, making differentiation on delivery biology and payload versatility especially important. For investors in France, Belgium and Switzerland, the key point is that Generation Bio should be viewed as a high-risk, high-upside platform company whose value depends on proving that its delivery system can work reproducibly in humans.
Recent developments in 2025 have been notable. Generation Bio reported new preclinical data showing selective siRNA delivery to T cells in non-human primates through its ctLNP system, supporting the company’s thesis that the platform can potentially extend genetic medicine into new cell types. Management has also stated that it is evaluating strategic alternatives to maximize shareholder value, and the company has undertaken a major workforce reduction as part of a broader restructuring effort. Together, these developments suggest a company in transition: scientifically active, financially cautious, and focused on preserving capital while seeking evidence that could unlock a strategic or clinical inflection point.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
